Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report

This report describes a case of lung adenocarcinoma harboring an echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase (EML4–ALK) fusion, high programmed death-ligand 1 (PD-L1) expression, and a Bcl-2-like protein 11 (BIM) deletion polymorphism. The patient was initially treate...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Meiyuan Lin, Yuan Gao, Jun Deng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-12-01
coleção:	Frontiers in Oncology
Assuntos:	ivonescimab non–small cell lung cancer ALK fusion drug resistance BIM deletion polymorphism case report
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1723763/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!